Literature DB >> 9579537

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.

L M Imbertson1, J M Beaurline, A M Couture, S J Gibson, R M Smith, R L Miller, M J Reiter, T L Wagner, M A Tomai.   

Abstract

ALDARA (imiquimod cream 5%) recently became available for the treatment of genital and perianal warts; however, the topical mechanism of action of imiquimod is not fully understood. Imiquimod, and its analogs R-842, S-27609, and S-28463, are potent anti-viral and anti-tumor agents in animal models. Much of the biologic activity of these compounds can be attributed to the induction of cytokines, including interferon-alpha, tumor necrosis factor-alpha, interleukins-1, -6, -8, and others. This study was performed to characterize the response of mice and rats to topical application of imiquimod and S-28463 and also to evaluate these agents in cultures of murine and human skin cells. Topical administration of imiquimod or S-28463 to the flanks of hairless mice and rats leads to increases in local concentrations of interferon and tumor necrosis factor in the skin. The concentrations of interferon and tumor necrosis factor were higher at the site of drug application than in skin from the contralateral flank or skin from untreated animals. Interferon-alpha mRNA levels were also elevated in the skin of mice after topical application of either imiquimod or S-28463. In vitro, both imiquimod and S-28463 induced increases in interferon and tumor necrosis factor in cultures of cells isolated from hairless mouse skin. Imiquimod also increased interleukin-8 concentrations in human keratinocyte and fibroblast cultures, whereas S-28463 induced increases in tumor necrosis factor in fibroblast cultures. These results demonstrate that imiquimod and S-28463 stimulate production of cytokines in the skin after topical application, which may play a major role in its activity in genital wart patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579537     DOI: 10.1046/j.1523-1747.1998.00174.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

2.  Human in vitro skin organ culture as a model system for evaluating DNA repair.

Authors:  Hannah Liu; Papapit Tuchinda; Rita Fishelevich; Erin Harberts; Anthony A Gaspari
Journal:  J Dermatol Sci       Date:  2014-02-16       Impact factor: 4.563

3.  A novel vacuum assisted closure therapy model for use with percutaneous devices.

Authors:  Saranne J Cook; Francesca R Nichols; Lucille B Brunker; Kent N Bachus
Journal:  Med Eng Phys       Date:  2014-03-27       Impact factor: 2.242

Review 4.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

5.  A new role for microRNAs, as ligands of Toll-like receptors.

Authors:  Muller Fabbri; Alessio Paone; Federica Calore; Roberta Galli; Carlo M Croce
Journal:  RNA Biol       Date:  2013-01-07       Impact factor: 4.652

Review 6.  Topical imiquimod: a review of its use in genital warts.

Authors:  C M Perry; H M Lamb
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

7.  Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

Authors:  J Moisan; W Wojciechowski; C Guilbault; C Lachance; S Di Marco; E Skamene; G Matlashewski; D Radzioch
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  The effect of imiquimod on taste bud calcium transients and transmitter secretion.

Authors:  Anthony Y Huang; Sandy Y Wu
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

Review 9.  Toll-like receptors in skin infections and inflammatory diseases.

Authors:  Yuping Lai; Richard L Gallo
Journal:  Infect Disord Drug Targets       Date:  2008-09

10.  Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.

Authors:  Daniel N Sauder; Michael H Smith; Therese Senta-McMillian; Inmaculada Soria; Tze-Chiang Meng
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.